Serum periostin across asthma severity strata in Indian children: a single-center exploratory cross-sectional study
This single-center exploratory study in Indian children demonstrates that serum periostin levels exhibit a strong, graded association with asthma severity and outperform routine eosinophil indices, though multicenter validation is required before clinical implementation.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Asthma is a common condition where the airways in the lungs become inflamed and narrow, making it hard to breathe. For children, managing this disease is often difficult because the standard tools used to measure how bad the condition is, such as breathing tests that require blowing hard into a machine, are frequently unreliable or simply unavailable in many parts of the world. Doctors often have to guess the severity of a child's asthma based on how many symptoms they have or what medicines they are taking. This uncertainty can make it hard to choose the right treatment. Scientists have been looking for a better way to measure the disease, hoping to find a simple biological signal in the blood that reflects what is happening inside the lungs. One such signal is a protein called periostin. This protein is produced by cells in the airways when they are irritated by specific chemical signals from the immune system. It helps build up scar tissue and attracts immune cells that cause inflammation. In adults, high levels of this protein have been linked to more severe asthma, but there is very little information about how it behaves in children, particularly in India, where genetic and environmental factors might change how the disease presents.
Researchers at a medical college in southern India set out to explore this question by looking at the blood of eighty children between the ages of six and eighteen. They divided these children into four equal groups: twenty healthy children with no history of asthma, and sixty children with asthma who were categorized as having mild, moderate, or severe disease based on the intensity of the medication they needed to stay well. The team collected blood samples from all the children and measured the amount of periostin in the serum, which is the liquid part of the blood. They also checked standard blood counts, including the number of eosinophils, a type of white blood cell often associated with allergies and asthma, to see if the new protein offered any advantage over these routine tests.
The results showed a clear and steady pattern. The amount of periostin in the blood rose step by step as the severity of the asthma increased. The healthy children had a median level of 38.8 picograms per milliliter. The children with mild asthma had a median of 53.2 picograms per milliliter. Those with moderate asthma showed a median of 75.2 picograms per milliliter, and the children with severe asthma had the highest levels, with a median of 95.2 picograms per milliliter. This difference was so distinct that the levels in each group were clearly higher than the group just below them. The protein levels also matched very closely with how well the children's symptoms were controlled; higher levels meant poorer control of the disease. When the researchers adjusted their analysis to account for other factors like age, sex, body mass, and whether the child had allergies, the link between the protein levels and the severity of the asthma remained strong and independent.
In contrast, the routine blood tests did not show the same clear picture. The number of eosinophils in the blood did not differ significantly between the healthy children and the various groups of asthmatic children. In fact, the eosinophil counts were slightly lower in the severe group compared to the milder cases, which is the opposite of what one might expect if the blood count were a reliable marker of disease intensity. This suggests that the standard blood test for eosinophils was not sensitive enough to track the severity of the disease in this group of children, likely because the asthma medications they were taking suppressed the eosinophil numbers in their blood, while the periostin levels remained high.
The study also looked at whether measuring this protein could help distinguish between children who have asthma and those who do not, or between those with severe disease and those with milder forms. The data suggested that the protein was very good at separating these groups within this specific study. However, the researchers are careful to note that these results come from a single hospital and a carefully selected group of children who were chosen to have equal numbers in each category. This design helps in comparing the groups but does not reflect the natural mix of patients seen in a typical clinic. Because the groups were artificially balanced and the test was not checked against a different set of patients, the high accuracy numbers reported here are likely optimistic and cannot yet be used to make clinical decisions.
Ultimately, this work provides a promising signal that serum periostin could be a useful tool for understanding asthma severity in children, especially in settings where advanced lung function tests are not available. The protein tracked the disease severity much better than the standard eosinophil blood count did. However, the findings are preliminary. The researchers emphasize that before this test can be recommended for everyday use, it needs to be tested in larger, more diverse groups of children across different centers to confirm that the results hold true in the real world. Until then, the protein remains a hopeful candidate for a future biomarker rather than a current standard of care.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.